JAK2 inhibitor
- JAK2 carries the EPO, TPO and GM-CSF signals; constitutive JAK2 drive defines the myeloproliferative neoplasms
- Shrinks the spleen and quiets cytokine symptoms in myelofibrosis; does not clear the clone
- On-target cost: anemia and thrombocytopenia
- JAK2 carries the EPO, TPO and GM-CSF signals; constitutive JAK2 drive defines the myeloproliferative neoplasms
- Shrinks the spleen and quiets cytokine symptoms in myelofibrosis; does not clear the clone
- On-target cost: anemia and thrombocytopenia
The JAK family at a glance
Four kinases, paired on cytokine receptors
- JAK1 + JAK3 — γ-common-chain cytokines (IL-2, -4, -7, -9, -15, -21)
- JAK2 + JAK2 — EPO, TPO, GH, GM-CSF
- JAK1 + TYK2 — type I interferons; JAK2 + TYK2 — IL-12, IL-23
Open the JAK inhibitors presentation →
Drugs with this mechanism (6)
- Baricitinib — Oral JAK1/JAK2 inhibitor for rheumatoid arthritis, alopecia areata, and severe COVID-19.
- Fedratinib — JAK2/FLT3 inhibitor for myelofibrosis.
- Momelotinib — JAK/ACVR1 inhibitor for myelofibrosis with anemia; improves spleen, symptoms, and transfusion burden.
- Pacritinib — JAK2 inhibitor that spares JAK1; designed for myelofibrosis with severe thrombocytopenia.
- Peficitinib — Oral JAK inhibitor used for rheumatoid arthritis in some countries; serious infection and herpes-zoster risks.
- Ruxolitinib — JAK1/2 inhibitor for myelofibrosis and polycythemia vera; abrupt stop causes a cytokine flare.
All mechanisms · Open JAK2 inhibitor in the interactive console ↗